Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis
September 14, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...
Raptor Pharmaceutical to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference
May 06, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will present at the following conference:
Julie Anne Smith, President and Chief...
Raptor Pharmaceutical to Hold First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, May 7, 2015 at 4:30 p.m. EDT
April 30, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2015 financial results on Thursday, May 7, 2015...